ImmunoPrecise Antibodies (IPA) Competitors $2.00 -0.02 (-0.99%) Closing price 04:00 PM EasternExtended Trading$2.02 +0.02 (+1.00%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. ATXS, NBTX, FULC, IVA, TNXP, AURA, ARCT, CRVS, ABEO, and OLMAShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Astria Therapeutics (ATXS), Nanobiotix (NBTX), Fulcrum Therapeutics (FULC), Inventiva (IVA), Tonix Pharmaceuticals (TNXP), Aura Biosciences (AURA), Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Astria Therapeutics Nanobiotix Fulcrum Therapeutics Inventiva Tonix Pharmaceuticals Aura Biosciences Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Astria Therapeutics (NASDAQ:ATXS) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do insiders and institutionals hold more shares of ATXS or IPA? 99.0% of Astria Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 4.5% of Astria Therapeutics shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, ATXS or IPA? Astria Therapeutics has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Does the media refer more to ATXS or IPA? In the previous week, Astria Therapeutics had 17 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 19 mentions for Astria Therapeutics and 2 mentions for ImmunoPrecise Antibodies. Astria Therapeutics' average media sentiment score of 0.99 beat ImmunoPrecise Antibodies' score of 0.44 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Astria Therapeutics Positive ImmunoPrecise Antibodies Neutral Do analysts prefer ATXS or IPA? Astria Therapeutics presently has a consensus price target of $29.00, suggesting a potential upside of 323.36%. ImmunoPrecise Antibodies has a consensus price target of $4.00, suggesting a potential upside of 100.00%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Astria Therapeutics is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, ATXS or IPA? ImmunoPrecise Antibodies has higher revenue and earnings than Astria Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$94.26M-$1.87-3.66ImmunoPrecise Antibodies$17.59M5.25-$21.69M-$0.68-2.94 Is ATXS or IPA more profitable? Astria Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -122.10%. ImmunoPrecise Antibodies' return on equity of -40.62% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -56.39% -36.08% ImmunoPrecise Antibodies -122.10%-40.62%-22.19% SummaryAstria Therapeutics and ImmunoPrecise Antibodies tied by winning 8 of the 16 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.23M$2.00B$5.67B$9.83BDividend YieldN/AN/A3.79%4.08%P/E Ratio-2.9432.5030.5825.12Price / Sales5.255.24464.55116.64Price / CashN/A50.5937.4059.05Price / Book5.415.889.096.18Net Income-$21.69M-$62.35M$3.25B$264.89M7 Day PerformanceN/A4.23%4.76%2.66%1 Month Performance9.89%0.23%6.72%3.05%1 Year Performance122.22%20.55%30.51%25.05% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.2837 of 5 stars$2.00-1.0%$4.00+100.0%+197.1%$93.23M$17.59M-2.9480Short Interest ↑Gap UpATXSAstria Therapeutics2.7103 of 5 stars$6.68+6.4%$29.00+334.1%-32.3%$354.41MN/A-3.5730Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionNBTXNanobiotix0.6779 of 5 stars$7.18-2.8%$8.00+11.5%+70.5%$353.82M$39.18M0.00100Positive NewsShort Interest ↑Gap UpFULCFulcrum Therapeutics1.5025 of 5 stars$6.34-2.3%$7.57+19.4%-26.8%$351.05M$80M-5.20100IVAInventiva3.6192 of 5 stars$3.52-1.7%$10.40+195.5%+93.6%$342.47M$9.95M0.00100Short Interest ↓Gap DownTNXPTonix Pharmaceuticals3.0698 of 5 stars$44.97-3.3%$70.00+55.7%+18.1%$342.04M$10.09M-0.0250Trending NewsEarnings ReportAnalyst RevisionGap DownTrading HaltedAURAAura Biosciences2.3391 of 5 stars$6.84+0.6%$22.00+221.6%-10.0%$341.83MN/A-3.6050News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionARCTArcturus Therapeutics2.8717 of 5 stars$11.39-4.4%$50.80+346.0%+0.1%$323.01M$152.31M-4.50180Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9062 of 5 stars$4.37+1.4%$15.00+243.2%+39.0%$321.15MN/A-4.3330News CoverageAnalyst RevisionABEOAbeona Therapeutics4.1532 of 5 stars$6.28+0.3%$19.25+206.5%+46.1%$320.24M$3.50M-4.9490Trending NewsEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals1.6409 of 5 stars$4.57-1.5%$24.50+436.1%-56.2%$317.48MN/A-2.2770News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Astria Therapeutics Alternatives Nanobiotix Alternatives Fulcrum Therapeutics Alternatives Inventiva Alternatives Tonix Pharmaceuticals Alternatives Aura Biosciences Alternatives Arcturus Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Abeona Therapeutics Alternatives Olema Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access